Literature DB >> 27753042

Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.

Johannes Fredebohm1, Daniel H Mehnert2, Ann-Kathrin Löber2, Frank Holtrup2, Vanessa van Rahden2, Philipp Angenendt2, Frank Diehl3.   

Abstract

We have designed a highly sensitive assay based on the Safe-SeqS technology to detect de novo mutations in the KIT gene and tested its performance. This assay was applied to plasma samples of GIST patients before and after treatment with regorafenib (GRID III trial) and mutations at known and novel sites of potential secondary resistance were identified.

Entities:  

Keywords:  GIST; KIT; NGS; Safe-SeqS; Secondary resistance; ctDNA

Mesh：

Substances：

Year:  2016        PMID： 27753042     DOI： 10.1007/978-3-319-42044-8_34

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  6 in total

Review 1.  Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer.

Authors:  Hanadi El Achi; Joseph D Khoury; Sanam Loghavi
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

Review 2.  Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management.

Authors:  Julie A Vendrell; Frédéric Tran Mau-Them; Benoît Béganton; Sylvain Godreuil; Peter Coopman; Jérôme Solassol
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

3.  Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis.

Authors:  Begona Jimenez Rodriguez; Gema Diaz Córdoba; Alicia Garrido Aranda; Martina Álvarez; Luis Vicioso; Casilda Llácer Pérez; Cristina Hernando; Begoña Bermejo; Ana Julve Parreño; Ana Lluch; Matthew B Ryder; Frederick S Jones; Johannes Fredebohm; Frank Holtrup; María Isabel Queipo-Ortuño; Emilio Alba
Journal:  J Clin Med       Date:  2019-08-07       Impact factor: 4.241

Review 4.  The Role Of Circulating Tumor DNA In Therapeutic Resistance.

Authors:  Chenxin Xu; Haixia Cao; Chen Shi; Jifeng Feng
Journal:  Onco Targets Ther       Date:  2019-11-08       Impact factor: 4.147

Review 5.  Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.

Authors:  Maha Elazezy; Simon A Joosse
Journal:  Comput Struct Biotechnol J       Date:  2018-10-09       Impact factor: 7.271

6.  Biotinylated amplicon sequencing: A method for preserving DNA samples of limited quantity.

Authors:  Karen Cravero; Arielle Medford; Aparna Pallavajjala; Jenna Canzoniero; Natasha Hunter; David Chu; Rory L Cochran; Ian Waters; Eric S Christenson; Kelly Kyker-Snowman; Berry Button; Alex J Cole; Ben Ho Park
Journal:  Pract Lab Med       Date:  2018-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.